Although AOM options have been limited for the pediatric population (11), glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) show significant beneficial effects on both BMI and metabolic health for the treatment of obesity in adults as well as in children and adolescents (4, 12, 13). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.